A Cost Variation Analysis of Oral Contraceptive Pills available in the Indian market
Abstract
Background: Oral Contraceptive Pills (OCPs) are highly effective contraceptives if used regularly and adequately, and they also have added non-contraceptive benefits. This gives way to their increasing use in recent years, which has led to the introduction of numerous brands of drugs with different costs in the Indian market. Hence the current study was conducted to analyze the cost ratio and cost variation of different brands of OCPs available in the Indian market and to compare the cost of branded and generic drugs. Materials and Methods: The cost of the drugs was obtained from the Current Index of Medical Specialties (CIMS) - 44th Year April – July 2022 and from the website https://www.mims.com/india/. The Cost Ratio (CR) and Percentage Cost Variation (CV) was calculated. The cost of generic drugs was obtained from the website http://janaushadhi.gov.in/SortingView.aspx. Results: 124 brands of various OCPs were available in the Indian market. Among all the regular OCPs available, the CR and CV were highest for Ormeloxifene 30mg at 10.19 and 919.4%, respectively, and they were lowest for Dienogest +Ethinylestradiol which comes under combined OCPs with the results of 1.007 and 0.73% respectively. The cost of all generic OCPs was lesser when compared with brand OCPs, and the difference in cost was maximum for Ulipristal. Conclusion: There is wide variation in the cost of Oral Contraceptive Pills available in the Indian market, and the cost of brand drugs is higher than their generic counterparts. Physicians have to be made aware of this price difference so that they can prescribe drugs that are more affordable to the patients to improve their adherence to the regimen.Dutta DC. Contraception. In: Konar H, editor. DC Dutta’s textbook of gynecology. 6th Ed. New Delhi: Jaypee brothers medical publishers (P) LTD; 2013.p.475-504.
International Institute of Population Sciences, Mumbai. National Family Health Survey (NFHS - 5). India report 2019-21. Available at: NFHS-5_INDIA_REPORT.pdf (rchiips.org). Published 2022.
Tripathi KD. Estrogens, Progestins and Contraceptives. In: Essentials of medical pharmacology. 8th Ed. New Delhi: Jaypee brothers medical publishers (P) LTD; 2019.p.330-53.
Kamboj VP. Centchroman A safe reversible postcoital contraceptive with curative and prophylactic activity in many disorders. Front Biosci (Elite Ed). 2018; 10(1):1–14.
Chrousos GP. The Gonadal Hormones & Inhibitors. In: Katzung BG, editor. Basic & Clinical Pharmacology. 14th Ed. New York, NY: McGraw-Hill Education; 2017.p.720-46.
Lalan HN, Borde MK, Ray I, Deshmukh Y. Cost variation study of antidiabetics: Indian scenario. Indian J Appl Res. 2011; 4(5):420–1.
Deepika PL, Priyambada S. Cost analysis of oral anti‐platelet drugs: a pharmacoeconomic study. Natl J Physiol Pharm Pharmacol. 2018; 8(2):215‐8.
Morgan SG, Lee A. Cost-related non-adherence to prescribed medicines among older adults: a cross-sectional analysis of a survey in 11 developed countries. BMJ Open. 2017; 7(1):e014287.
Atal S, Atal S, Deshmankar B, Nawaz SA. Cost analysis of commonly used drugs under price control in India: Assessing the effect of drug price control order on brand price variation. Int J Pharm Pharm Sci 2016; 8:315-21.
Sakthivel S. Access to essential drugs and medicines. In: Lal PG, editor. National Commission on Macroeconomics and Health. New Delhi: Ministry of Health; 2005. p. 185-210.
Kolasani BP, Malathi DC, Ponnaluri RR. Variation of cost among anti-cancer drugs available in Indian market. J Clin Diagn Res. 2016; 10(11):FC17–20.
Phulpagare MB, Tiwari SA, Hiray RS. Cost Excursion Study of Various Insulin Preparations Available in India.J Clin of Diagn Res.2021; 15(7):FC01-FC05.
Sharmila Sinha, Tejus A. A cost variation analysis of the antihypertensives: The need for essential of medicines list to fit the bill. MedPulse International Journal of Pharmacology. July 2019; 11(1): 06-12.
Shukla AK, Mehani R. Cost analysis of antiepileptic drugs available in India. Int J Basic Clin Pharmacol 2016; 5:1636-40.
Shyam S, Mahanthegowda BD. A cost variation analysis of various brands of oral anti-diabetic drugs currently available in Indian pharmaceutical market. Int J Basic Clin Pharmacol 2020;9:1253-7
Roy V, Gupta U, Agarwal K. Cost of medicines and their affordability in private pharmacies in Delhi (India) Indian J Med Res. 2012;136(5):827–35.
Drug Cost Control Order, 2013, Government of India. Available at: http://www.nppaindia.nic.in/DPCO2013.pdf. [Accessed on 2023 January 24]
Manjhi PK, Kumar C, Rana AK. Rational use and cost variation analysis of antifungal drugs available in the Indian market: a pharmacoeconomic study. Int J Basic Clin Pharmacol 2022; 11:602-6.
King DR, Kanavos P. Encouraging the use of generic medicines: Implications for transition economies. Croat Med J. 2002; 43:462-9.
Dylst P, Simoens S. Does the market share of generic medicines influence the price level?: a European analysis: A European analysis. Pharmacoeconomics. 2011; 29(10):875–82.
Pichholiya M, Basu A, Yadav AK, Kothari N, Tahashildar J. An observational comparative study of cost between branded medicines and generic medicines. Int J Basic Clin Pharmacol. 2017 Jan. 21; 4(2):269-72.
Rana P, Roy V. Generic medicines: issues and relevance for global health. Fundam Clin Pharmacol. 2015; 29(6):529–42.
Joshi SS, Shetty YC, Karande S. Generic drugs - The Indian scenario. J Postgrad Med [Internet]. 2019;65(2):67–9.
| Files | ||
| Issue | Vol 9 No 2 (2023) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/jppm.v9i2.13368 | |
| Keywords | ||
| Oral Contraceptive Pills Cost Variation Cost ratio Pharmacoeconomics | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
